Navigation Links
Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
Date:5/7/2013

ver, abnormal elevations of B-cells and BAFF may lead to an overactive immune response which may damage normal healthy tissues and organ systems. Multiple clinical studies with BAFF antagonists have reported the potential benefit of BAFF inhibitors' in treating patients with lupus and rheumatoid arthritis.

In April 2012, Anthera completed the PEARL-SC Phase 2b clinical study to evaluate the efficacy and safety of subcutaneous blisibimod in patients with active and seropositive lupus. In June and July of 2012 Anthera announced results from PEARL-SC which led to the initiation of a Phase 3 registration plan utilizing the 200mg weekly dose of blisibimod in patients who were afflicted with active lupus despite receiving corticosteroids.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual resul
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
2. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
3. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
4. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
5. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
6. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
7. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
8. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
9. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
10. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 ,Weight Loss- Market Analysis, ... report provides comprehensive insights about phase III pipeline drugs ... of the report is to establish the understanding for ... across the different countries and regions. While the leading ... also provides details on the drug master filings across ...
(Date:8/18/2014)... Calif. , Aug. 18, 2014 ... therapeutics to treat infectious diseases, has announced intentions ... the treatment of the current Ebola Virus outbreak ... the use of GBV006, a combination of Food ... established compassionate use regulatory pathway.  The discovery of ...
(Date:8/18/2014)... 2014  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... Tomasello as its Chief Commercial Officer.  Ms. Cline ... of the Americas, Hematology and Oncology, for the Celgene ... Prior to joining Celgene, Ms. Cline Tomasello was the ... Genentech, where she was responsible for over $1.7 billion ...
Breaking Medicine Technology:Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 2Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 3Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 4Pharmacyclics Appoints Chief Commercial Officer 2Pharmacyclics Appoints Chief Commercial Officer 3Pharmacyclics Appoints Chief Commercial Officer 4
... DELAND, Fla., May 13 USHIFU, LLC, the clinical ... pleased,to announce conditional written approval pending minor changes to ... for the treatment of,recurrent prostate cancer with the Sonablate(R) ... Dr. Herbert Lepor, Chairman of Urology at NYU ...
... Products Expand Infection Prevention Business, DUBLIN, Ohio, ... products and services that improve the safety and,productivity ... the,acquisition of assets of privately held Enturia, Inc., ... ChloraPrep(R) brand name., ChloraPrep(R) brand products are ...
Cached Medicine Technology:FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer 2Cardinal Health Completes Enturia Acquisition 2
(Date:8/19/2014)... LunaDress, a popular supplier of fashionable ... ladies, is now providing a discount of up to ... company’s cheap white prom outfits are available in different ... outfits. , There are over 400 cheap white ... the special offer is valid until August 29, 2014. ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, iFitDress.com,a ... occasion outfits, has unveiled its new collection of ... made to expand the company’s global market. Each item ... to the company’s senior spokesman, customers that have specific ... at iFitDress.com. Now, all the brand new items are ...
(Date:8/19/2014)... 2014 The National Cannabis Industry ... Southwest CannaBusiness Symposium on Saturday, August 23, from ... in Las Vegas. , Featuring keynotes by U.S. Representative ... (D-Las Vegas), the event will also include in-depth discussions ... NCIA is doing federally to advance a legitimate and ...
(Date:8/19/2014)... Drews Dental Services is proud to announce the recent election ... Maine Dental Association (MDA). After serving on the Executive Board ... been sworn in to his new position. , Dr. Drews ... and being a part of the ADA House of Delegates ... 2015. He plans to advocate for the profession of dentistry ...
(Date:8/19/2014)... Tara Haelle HealthDay ... -- Kidney injury can be added to the list ... medications often prescribed to treat behavioral symptoms of dementia ... (Seroquel), risperidone (Risperdal) and olanzapine (Zyprexa) are approved by ... disorder, schizophrenia and other serious mental disorders. They are ...
Breaking Medicine News(10 mins):Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:SATURDAY IN LAS VEGAS: U.S. Rep. Dina Titus, State Sen. Tick Segerblom Keynote National Cannabis Industry Association Southwest CannaBusiness Symposium 2Health News:Dr. Drews Elected VP of Maine Dental Association 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3
... Five former directors of the Population and Reproductive Health ... (USAID) today urged the new Obama administration to move ... . The former directors issued a joint report, ... Assistance, as Barack Obama takes office as president. ...
... K. Shinseki took the oath of office today as ... leadership of the Department of Veterans Affairs following Tuesday,s ... from my first day in office is to make ... focused on the Nation,s Veterans as its clients," Shinseki ...
... 21 The following statement can be attributed ... BlueCross:"Capital BlueCross has consistently said two things: We ... other merger. But we have urged public policy ... this proposed merger without conditions, because without conditions ...
... low levels of sexual desire, often as a result of ... physical symptoms such as back pain and memory problems than ... new study by researchers at the University of North Carolina ... study, published recently as an online early view article in ...
... history was made 10 years ago, greatly impacting the ... when a team of surgeons performed the first hand ... procedure, also called composite tissue allotransplantation, criticized by some ... in the world of organ transplantation, has continued to ...
... IDEXX Laboratories, Inc. (Nasdaq: IDXX ), has scheduled ... results for Friday, January 30, at approximately 7:00 a.m. (eastern). ... 9:00 a.m. (eastern) on that day. Individuals can access a ... the IDEXX Web site, www.idexx.com . An archived edition ...
Cached Medicine News:Health News:Five Former USAID Officials Ask Obama for Leadership on Family Planning 2Health News:Shinseki Sworn In, Vows 21st Century Service to Veterans 2Health News:Capital Blue Cross Issues Statement on Withdrawal of Merger 2Health News:UNC study: Postmenopausal women's loss of sexual desire affects health, quality of life 2Health News:Hand Transplantation Marks Historical 10-Year Milestone 2Health News:Hand Transplantation Marks Historical 10-Year Milestone 3Health News:Hand Transplantation Marks Historical 10-Year Milestone 4
... The Awaya stereo test was developed to ... Awaya Stereo test employs the more reliable ... eye. It is not dependent on polarizing spectacles ... first target is an attractive image of a ...
... is designed to assist patients with red-green color ... filter cuts off wavelengths shorter than 582 nm ... of their most difficult color distinctions. A color ... determine whether a color is in the longer ...
Features a twist-on backswitch, with a diffused, cobalt blue light beam....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
Medicine Products: